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ABSTRACT  
Pathologies affecting the optic nerve and the retina are one of the major causes of 
blindness. These diseases include age-related macular degeneration (AMD), diabetic 
Retinopathy (DR) and glaucoma, among others. Also, there are genetic disorders that 
affect the retina causing visual impairment. The prevalence of neurodegenerative diseases 
of the posterior segment are increased as most of them are related with the elderly. Even 
with the access to different treatments, there are some challenges in managing patients 
suffering retinal diseases. One of them is the need for frequent interventions. Also, an 
unpredictable response to therapy has suggested that different pathways may be playing 
a role in the development of these diseases. The management of these pathologies requires 
the development of controlled drug delivery systems able to slow the progression of the 
disease without the need of frequent invasive interventions, typically related with 
endophthalmitis, retinal detachment, ocular hypertension, cataract, inflammation, and 
floaters, among other. Biodegradable microspheres are able to encapsulate low molecular 
weight substances and large molecules such as biotechnological products. Over the last 
years, a large variety of active substances has been encapsulated in microspheres with the 
intention of providing neuroprotection of the optic nerve and the retina.  
The purpose of the present review is to describe the use of microspheres in chronic 
neurodegenerative diseases affecting the retina and the optic nerve. The advantage of 
microencapsulation of low molecular weight drugs as well as therapeutic peptides and 
proteins to be used as neuroprotective strategy is discussed. Also, a new use of the 
microspheres in the development of animal models of neurodegeneration of the posterior 
segment is described. 
 
 
KEYWORDS: Microspheres, Protein release, Age-Related-Macular Degeneration 
(AMD); Glaucoma; Diabetic Retinopathy (RD); Neuroprotection; Animal models; 
Peptides reléase. 
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ABBREVIATIONS 
 
Age-related macular degeneration (AMD) 
Arising retinal pigment epithelial cells (ARPE) 
Basic fibroblast growth factor (b-FGF)  
Bovine serum albumin (BSA) 
Brain-derived neurotrophic factor (BDNF) 
Central nervous system (CNS) 
Ciliary neurotrophic factor (CNTF)  
Circular dichroism (CD) 
Corneal neovascularization (CNV) 
Cyclooxigenase (COX) 
Diabetic retinopathy (DR) 
Diethylamine-azobenzene-quaternary ammonium (DENAQ) 
Electroretinography (ERG) 
Enzyme-Linked ImmunoSorbent Assay (ELISA) 
Erythropoietin (EPO) 
Glial cell-line derived neurotrophic factor (GDNF) 
GDNF family ligands (GFLs) 
Human Umbilical Vein Endothelial Cells (HUVECs) 
Inner Nuclear Layer (INL) 
Inner plexiform layer (IPL) 
Intraocular drug delivery system (IDDS) 
Intraocular pressure (IOP)  
Matrix metalloproteinase 2 (MMP-2) 
Microspheres (MS) 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
Outer Nuclear Layer (ONL) 
Phosphate-buffered saline (PBS) 
Poly (lactic-co-glycolic) acid (PLGA) 
Poly (ester amide)s (PEAs) 
Poly (lactic) acid (PLA) 
Poly-beta amino ester (PBAE) 
Polyethylene glycol (PEG) 
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Quaternary ammonium-azobenzene-quaternary ammonium (QAQ)  
Radial peripapillary capillaries (RPCs) 
Retinal ganglion cells (RGCs) 
Retinal pigment epithelial cells (RPE) 
Retinitis pigmentosa (RP) 
Rod-phosphodiesterase (PDE) 
rod-phosphodiesterase (PDE) 
size-exclusion chromatography (SEC) 
Sodium dodecyl sulfate- Polyacrylamide gel electrophoresis (SDS-PAGE) 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
Transforming growth factor-β (TGF-β) 
Triamcinolone acetonide (TA)   
US Food and Drug Administration (FDA) 
Vascular endothelial growth factor (VEGF) 
Vitamin E (Vit E) 
 
 
 
1.- INTRODUCTION:  
 
Pathologies affecting the optic nerve and retina are one of the major causes of blindness. 
These diseases include age-related macular degeneration (AMD), diabetic retinopathy 
(DR) and glaucoma, among others (1-3). The prevalence of neurodegenerative diseases 
of the posterior segment has increased as most of them are related with the elderly (4). 
Also, there are genetic disorders that affect the retina causing visual impairment such as 
retinitis pigmentosa, Leber´s congenital amaurosis, Startgaard disease and choroideremia, 
among others. 
  
There are several clinical issues related to the management of neurodegenerative diseases 
affecting the retina or surrounding tissues. This is the case of neovascular age related 
macular degeneration and proliferative retinopathy patients affected that need frequent 
intravitreal injections of anti-VEGF agents. Also, it is important to notice the poor 
compliance in the treatment with antihypertensive drugs in glaucoma patients with high 
intraocular pressure (IOP) values. Neurodegeneration is other important issue as it is 
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present in glaucoma patients with high IOP values with no response to hypotensive 
therapy and in normotensive subjects.  
 
Delivery of active substances in therapeutic concentrations to the targeted intraocular 
tissues is restricted by the effective static (corneal layers, sclera, retina, blood aqueous 
and blood retinal barriers) and dynamic barriers (tear dilution, conjunctival and choroidal 
blood flow, and lymphatic clearance) as well as efflux pumps that are present in the eye 
(5) (fig 1). Instilled drugs have poor bioavailability in the intraocular tissues (6). For this 
reason, the ophthalmic topical administration is restricted to the treatment of pathologies 
involving the ocular surface or whether the pharmacological target is located in the 
anterior segment of the eye. Intraocular and periocular injections are used to release 
therapeutic molecules inside the eye. In the case of intravitreal injections the drug is 
injected close to the retinal tissues, which leads to the highest biovailability in the 
posterior segment tissues compared with the other local routes of administration. 
Although periocular injections are less invasive, the therapeutic molecule has to reach the 
posterior segment by diffusion through different tissues. 
Intravitreal injections are regularly used in the clinical practice for the treatment of 
posterior segment diseases. However, even with the available access to different ocular 
therapies, there are some challenges in the management of patients suffering retinal 
diseases. One of them is the need of frequent interventions. Also, an unpredictable 
response to therapy has suggested that different pathways may be playing a role in the 
development of these diseases. This might the reason why monotherapy is not enough to 
slow the progression of the degeneration (7). 
 
One of the most challenging areas in ophthalmology therapy is dedicated to decrease the 
number of interventions. Under the technological point of view this objective can be 
achieved thanks to the development of intraocular drug delivery systems (IDDS) (8). 
These devices are prepared with different biomaterials to provide sustained delivery of 
the active molecule close to the target site during long term. Depending on the properties 
of the biomaterial the IDDS can disappear from the site of administration (biodegradable) 
or remain during the lifetime of patients (non-biodegradable).  
According to their size, IDDS are classified as implants (size>1mm), microparticles (size 
1-1000m) or nanoparticles (1-1000nm). The different drug delivery systems are useful 
for the treatment of neurodegenerative diseases affecting the posterior segment of the eye. 
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The right choice of the most adequate IDDS depends on the target site, the ophthalmic 
disease and the duration of the treatment. While implants and microparticles deliver the 
drug for long periods of time, nanoparticles have the advantage to be internalised by cells 
being useful for gene therapy (9, 10). 
 
Implants are currently used in the clinical practice to provide long term delivery of 
therapeutic molecules. Several non-biodegradable (Vitrasert, Retisert and Medidur) 
and one biodegradable (Ozurdex) macrodevices are commercialised (8). 
  
Microparticulate systems are able to encapsulate and deliver the drug for several months. 
Attending to their structure, they received the name of microcapsules if the drug is 
surrounded by a polymer or polymer mixture (reservoir) and microspheres if the drug is 
dispersed in the polymer network (matrix). Injection of microparticles can be performed 
by using small gauge needles (25-32G). Personalised therapy is possible as different drug 
doses are administered depending on the amount of administered microparticles. 
Biodegradable microparticles are preferred as they gradually disappear from the site of 
administration (5).  
 
Biodegradable polymers (gelatin, albumin, polyorthoesters, polyanhydrides and 
polyesters) have been explored to prepare microspheres for intraocular administration. 
Among them, the poly(lactic) acid (PLA), poly(glycolic) (PGA) and their co-polymers 
poly(lactic-co-glycolic) acid (PLGA) are the most employed as they are approved for 
clinical purposes. The use of injectable microspheres has become more popular over the 
last few decades (5). Typical patterns of in vitro drug release from PLGA microspheres 
is presented in fig 2. As example of degradation behaviour, a schematic representation of 
PLGA microspheres evolution on release media is also included. 
 
The main objective of the design of microparticulate drug delivery systems has been to 
obtain long-acting injectable drug depot formulations. Biodegradable microspheres are 
able to encapsulate low molecular weight substances and large molecules such as 
biotechnological products. Over the last years, a large variety of active substances has 
been encapsulated in microspheres with the intention of providing neuroprotection of the 
optic nerve and retina. 
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The purpose of the present review is to describe the use of microspheres in 
neurodegenerative diseases affecting the retina and the optic nerve.  Also, a new use of 
the microspheres in developing animal models is discussed. 
 
2.- CHRONIC DISEASES OF THE OPTIC NERVE AND RETINA 
 
Advances in the understanding of pathogenesis that lead to retinal cell death have been 
essential to gain new insights about neurodegenerative diseases like age-related macular 
degeneration, diabetic retinopathy or glaucoma. These pathologies share a common 
pathophysiologic pathway that includes oxidative stress, axonal transport impairment, 
neuroinflammation, and excitotoxicity, which are the major cause of retinal cell death.  
 
2.1. Age-related macular degeneration 
 
Age-related macular degeneration (AMD) accounts for 8.7% of all blindness worldwide 
and is the most common cause in developed countries, especially in people older than 60 
years (11). This pathology is becoming more prevalent in the developing world due to an 
exponential population ageing. Differences in prevalence from diverse populations may 
offer insights into possible environmental and genetic causes of AMD (12). 
Environmental and behavioral factors for AMD include cigarette smoking, obesity, low 
dietary intake of vitamins A, C and E, zinc, lutein and omega-3 fatty acids, and an 
unhealthy lifestyle related to cardiovascular risk factors (13).  
 
AMD is characterized by a central vision loss due to degenerative alteration in the 
macular region of the retina (fig 3). The disease can be classified as dry or wet AMD, 
depending on the absence or presence of choroidal neovascularization, respectively. In 
wet AMD, the growth of new blood vessels from the choroid into the sub-retinal space 
and sub-retinal pigment epithelium is responsible for the vision loss (13). In addition, in 
both dry and wet AMD, the pathology manifests as pigmentary irregularities of the retina 
and deposits called drusen, which are accumulations of extracellular material 
immediately beneath the retinal pigment epithelium. Although drusen are a manifestation 
of the normal ageing process, they can represent an important sign associated with retinal 
disease (14). Patients usually develop rapid visual loss when neovascular AMD occurs. 
Typically, they describe sudden worsening of central vision with distortion of straight 
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lines, a dark patch in their central vision, or both. Treatment of wet AMD includes laser 
photocoagulation, photodynamic therapy, anti-VEGF therapy and visual rehabilitation. 
 
Laser photocoagulation is effective in reducing long-term severe visual loss, but is limited 
by lack of vision gain and high recurrence rates (50%), and a risk of immediate moderate 
visual loss (41%) (15). Photodynamic therapy consists of a two-stage process involving 
intravenous infusion of verteporfin, a green photosensitizing dye that accumulates 
preferentially in neovascular membranes, followed by a dye activation with infrared light 
(16). This process generates oxygen-free radicals that damage the endothelium, 
promoting closure of newly formed vessels. This therapy is not exempt from adverse 
events that include photosentivitity, headaches, acute severe visual loss (in 4% of 
patients), and chorioretinal atrophy able to lead to gradual visual deterioration (17). 
 
Progress in understanding the key role of vascular endothelial growth factor (VEGF) in 
choroidal neovascularization has led to the development of molecules that by blocking 
VEGF are able to partly revert some of the pathological mechanisms shown in 
neovascular AMD. Anti-VEGF drugs are typically administered by intravitreal injection, 
and include pegaptanib, ranibizumab, bevacizumab and aflibercept (18-24).  
 
2.2.- Diabetic retinopathy 
 
Diabetic retinopathy (DR) is a leading global cause of vision-loss. In 2010, it was 
estimated that around one third of 285 million people with diabetes mellitus worldwide 
had signs of DR (25). In approximately one third of people with DR, the pathology was 
vision-threatening, defined as severe retinopathy or macular edema (26). For progression 
of vision loss, the most clinically important risk factors are duration of diabetes, 
hyperglycemia and hypertension. Emerging evidence supports a genetic component for 
DR, showing a heritable tendency independent of shared risk factors (27-29).  
 
On the early stages of diabetic retinopathy, localized dilatations of the eye 
microvasculature appear in patients, which are assumed to be related with weaknesses in 
the vessel wall, pressure disturbances, or glial retraction/death (30). An increment in the 
appearance or disappearance of these microaneurysms has been found to be related with 
the progression of retinopathy and also with eventual visual function decrements (31). 
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Other lesions in early stages of the pathology, which are also important in the eventual 
progression to neovascularization, include capillary non-perfusion and degeneration (32, 
33). Both stimulate the release of hypoxia-regulated vasoproliferative factors, such as 
VEGF, correlated with an increase in neovascularization and vascular leakage. In 
advanced stages of DR, mechanisms of DR-related vision loss include vitreous 
hemorrhage, tractional retinal detachment from proliferative DR, development of a 
fibrovascular membrane in the vitreous, and macular edema (34) (fig. 4).  
 
To inhibit the development or progression of DR, several approaches are currently used 
in the clinical practice. In early stages of the pathology, interventions are directed towards 
control of blood pressure, hyperglycemia, and lipids. However, maintaining these 
parameters under control is challenging in many diabetic patients (35-38). In advanced 
stages of DR, treatments include pan-retinal laser photocoagulation, or intravitreal 
injections of anti-VEGF agents and steroids. Laser can largely control neovascularization 
and prevent blindness, however this treatment cannot restore vision, and, as mentioned 
before, it has vision-impairing effects of its own as well (39). Regarding the use of anti-
VEGF or steroids, they can significantly reduce macular edema (40, 41). Unfortunately, 
their beneficial effects have been found to be temporary in comparison with the effects 
of standard photocoagulation, and they are also associated with vision-threatening 
complications related to repeated intravitreal injection (41). Hence, given the limitations 
of these therapies, vision loss from DM is a significant healthcare concern (42).  
 
2.3.- Retinitis pigmentosa 
 
Retinitis pigmentosa (RP) refers to a group of inherited dystrophies characterized by 
progressive degeneration of the visual cells and abnormalities in retinal pigment 
epithelium, with an outcome of blindness typically achieved after several decades, during 
which vision is slowly and irreversibly lost (43). The prevalence of RP is 1:3000 to 1:7000. 
More than 3000 mutations in over 57 different genes and 61 loci are currently known to 
cause the non-syndromic form of RP (www.orpha.net). 
 
Night blindness, due impairment of rod photoreceptors, is the first manifestation of the 
disease and it typically manifests during early adolescence. Then, a progressive death of 
these cells is produced and, as a consequence, patients experience alterations of the visual 
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field. At the beginning, loss of rods is produced in the peripheral retina generating “tunnel 
vision” (fig. 5). Later, patients undergo a progressive deterioration of visual acuity in the 
central field as well as a decline of chromatic discrimination, due to the gradual cones 
death, which leads RP patients to a condition of legal blindness (44).  
 
Degeneration mechanisms of RP are complex, still poorly understood, and reveal multiple 
molecular targets, which make difficult the development of therapeutic strategies, 
maintaining this pathology as an orphan disease. However, although there is no cure for 
RP, there has been outstanding advance in underlying genetic and molecular mechanisms 
to understand the pathology, which has led to restoration of vision in specific cases, such 
as in patients with a mutation in a gene coding for the retinal pigment epithelium protein 
RPE65, essential for photoreceptor physiological activity (45, 46). Other strategies 
include the implantation of prosthesis in advanced stages of RP, when most rods and 
cones have been inevitably lost. The progress achieved in this field is extraordinary, and 
clinical trials for different types of implants have proceed successfully or are expected 
soon (47, 48). Molecules studied for RP have been designed for increasing 
neuroprotection with the use of neurotrophic factors, decreasing cellular oxidative stress, 
inhibiting photoreceptor apoptosis, or attenuating retinal inflammation. Unfortunately, 
pharmacological approaches to RP are still experimental and their main goal is not to 
repair RP, but rather to slow it down, enlarging the temporal window of useful vision (49).  
 
2.4.- Glaucoma 
 
Glaucoma comprises a group of disorders characterized by a distinctive optic neuropathy 
that leads to progressive asymptomatic visual field loss. It is thought that loss of vision 
in glaucoma is associated with damage to the optic nerve and retina that results in 
irreversible retinal ganglion cell (RGC) damage. Glaucoma is currently the leading cause 
of irreversible blindness worldwide. It has been estimated that the total number of patients 
with glaucoma will be close to 80 million by 2020 (50).  By the time patients are aware 
of vision loss, the disease is commonly quite advanced (51). Patients usually experience 
blurry or missing spots in their peripheral view (fig. 6).  
Increased IOP and IOP variability are recognized as significant risk factors both for the 
development and progression of glaucoma. For that reason, the majority of primary open-
angle glaucoma treatment options focus on the management and reduction of IOP (52-
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54). Current treatments involve the use of eye drops and gels, laser treatment, or incisional 
surgery to achieve a lower IOP by either decreasing aqueous humor production or 
improving aqueous outflow (51). It is important to remark that not all glaucomatous 
patients experience high IOP and in many cases, the reduction of IOP does not avoid the 
progression of the disease. 
 
Whatever the origin of the disease, in all glaucoma patients visual field loss is produced 
by RGCs death. Normal physiological ageing is responsible for an estimated rate of 0.4% 
RGC loss per year over approximately 1.5 million RGCs present in a healthy retina (55); 
in glaucoma, this percentage is increased to 4% (56). Considering the complex and 
multifactorial nature of glaucoma, multiple mechanisms are thought to contribute to RGC 
loss, such as apoptosis, necroptosis, axonal transport failure, inadequate neurotrophic 
factor support, excessive depolarization, mitochondrial dysfunction, excessive short-
wave blue light, excessive glutamate, oxidative stress, and inappropriate RCG/glial cell 
interactions (55, 57-61). Over the past years, many publications have related glaucoma to 
neuroprotection.  
 
3.- MICROENCAPSULATION OF SMALL MOLECULES FOR THE TREATMENT 
OF CHRONIC DISEASES OF THE OPTIC NERVE AND RETINA 
The clinical application of small drug molecules has been extensively studied for 
the treatment of neurodegenerative pathologies affecting the posterior segment of the eye. 
However, their clinical application is restricted due to the fast clearance they experience 
that requires frequent administrations to reach therapeutic levels in the target tissues (62). 
This limitation can be overcome by encapsulating these drugs into delivery systems such 
as polymeric microspheres, which allow sustained drug release, and subsequently a 
reduced-dosing indication (63). Microspheres can be administered locally without 
surgery. Such locally injected depots provide long-term sustained drug release, thus 
enabling the safe dosing of drugs with pharmacokinectics issues such as a rapid systemic 
clearance or a narrow therapeutic window (64). Many neuroprotective agents exhibit 
significant side effects when administered systemically. These side effects are severe 
enough to limit the dose, and ultimately, the efficacy of the drug. Successful treatment 
strategies may involve local, sustained delivery of these drugs in a way that maximizes 
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the efficacy while limiting side effect to an acceptable level. Drug loaded-microspheres 
are being developed with this intention as well (table 1).   
Corticosteroids 
Retinal vasculature diseases have become more prevalent as a result of aging 
population (65). Even with the growing use of anti-VEGF therapeutic agents, 
corticosteroids are still drugs of choice for the treatment of some of these disorders, and 
still are a big actor in the medical care due to their confirmed efficacy. It has been 
demonstrated that corticosteroids can increase tight junction integrity, protecting the 
blood-ocular barrier and decreasing leakage. Additionally, they have shown an 
antiapoptotic effect, and can protect retinal photoreceptors via activation of 
glucocorticoid receptors (66).   
Dexamethasone (Mw 392.5 g/mol) is a cortical steroid that has a very short 
vitreous half-life (67). Since the approval from the US Food and Drug administration of 
Ozurdex (Allergan), a long-acting implant containing dexamethasone for the treatment of 
posterior segment eye diseases, the development of microparticulate sustained release 
systems containing steroids has gained considerable attention. Contrary to the use of the 
implant Ozurdex, that has to be applied with a large needle (22 gauge), microparticulate 
formulations can be delivered though needles from 27 to 34 gauge, avoiding invasive 
surgery or the use of larger devices for their application. Several studies have been made 
to deliver dexamethasone from microparticles prepared with biodegradable polymers. 
Hou H. et al. investigated pharmacokinetics and pharmacodynamics of the engineered 
oxidized porous silicon (pSiO2) particles loaded with dexamethasone (width 20 ± 5 µm, 
thickness 14.2 ± 0.3 µm, porosity 50 ± 3%) in vitro and in vivo (68). After a 60-day in 
vitro release, particles demonstrated a 92% decrease by weight, indicative of pSi 
degradation and dexamethasone delivery in the dissolution chamber at 37ºC over time. 
Dexamethasone concentration was at a therapeutic level at the end of the 60-day in vitro 
release study (12.4 ng/mL). In vivo ocular pharmacokinetics in New Zealand Red Rabbits 
revealed a controlled drug release sustained for at least 8 weeks without apparent ocular 
toxicity. The study demonstrated the utility of porous silicon dioxide microparticles as 
carriers for controlled release of corticoids in ophthalmology. Andrés-Guerrero V et al 
(69) prepared dexamethasone-loaded microspheres based on poly(ester amide)s (PEAs), 
which are amino acid containing biodegradable polymers combining ester an amide 
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groups in the polymer chain. Their work focused on the study of the ability of PEAs to 
form microspheres for ophthalmic drug delivery purposes. In this study, authors showed 
the synthesis of the PEA polymers and the preparation, sterilization, in vitro tolerance 
and delivery characteristics of microspheres loaded with dexamethasone. Authors built a 
kinetic ocular model with in vitro release data to predict in vivo drug concentrations in a 
rabbit vitreous model. Then, they analyzed the behavior of PEA microspheres after 
injection in the subtenon space and vitreous humor of rats. Amino acid based 
polyesteramides were successfully formulated into microspheres (~15 μm), which 
showed good tolerance in macrophages and retinal pigment epithelial cells. Loading and 
release studies with dexamethasone revealed high drug encapsulation efficiency (~85%) 
and a controlled drug delivery for 90 days. Pharmacokinetic simulations indicated that 
these microspheres would provide a release of the drug in rabbit eyes up to 3 months. 
After 24 h of the administration, the injected PEA microspheres retained their 
morphology and coalesced into depots in the vitreous and in the subtenon space, 
successfully reaching the injection site, showing the utility of polyesteramide 
microspheres as an alternative delivery system for controlled delivery of drugs to the eye. 
Triamcinolone acetonide (TA) is a synthetic corticosteroid (Mw 434.5 g/mol) with 
a 7.5-fold higher anti-inflammatory potency than cortisone. It is one of the most 
extensively used drugs in the treatment of several ocular diseases which are characterized 
by inflammation, edema and neovascularization (70). Triamcinolone acetonide is a water 
insoluble drug so its use in ophthalmology is available as an injectable suspension. 
Suspensions are required to be made with the insoluble drug in a micronized form, and 
are thought to be acceptable as a depot since it is assumed that the solid drug persists in 
the injection site giving rise to a sustained-release effect thanks to a slow dissolution rate 
of the poor soluble drug. However, suspensions have some disadvantages, such as not 
being possible to manipulate the concentration of dissolved drug due to their relative 
insolubility in the vehicle. For this reason and, due to the increment on the use of 
intraocular injections of triamcinolone in ophthalmology, the development of intraocular 
drug delivery systems loaded with triamcinolone has increased in the past years (5).  
Cardillo el al. presented a case report with 9 patients that received intraocular 
injections of RETAAC, a controlled-release system based on microspheres loaded with 
1mg triamcinolone. Authors compared the use of this system with a single intravitreal 
injection of 4mg triamcinolone for the treatment of diffuse diabetic macular edema (71). 
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Quantitative measurements of central macular thickness showed a reduction from 
baseline exceeding 59% (RETAAC) and 56% (triamcinolone) at the 1- and 3-month 
follow-up visits respectively. The difference in central macular thickness between 
RETAAC and TA injected eyes was not significant because of a parallel initial pattern of 
regression of the macular edema. On the contrary, at 6 (p=0.002) and 12 months 
(p=0.002), RETAAC-injected eyes had thinner central macular thickness measurements 
compared to 4 mg triamcinolone injected eyes. According to the authors, the findings 
from this preliminary report neither advocate nor support the use of triamcinolone-
microspheres for the treatment of diabetic macular edema, but imply that both RETAAC 
and triamcinolone injections may be well tolerated with long-term performance clearly 
favoring the RETAAC (1 mg) over TA (4 mg) for the anatomic and functional aspects of 
improvement tested in the study.   
Blatsios et al. also evaluated a controlled-release system based on triamcinolone-
loaded poly[DL-lactide] (PLA) microspheres (72). Authors prepared several batches with 
different ratios of drug/polymer (5/100 and 10/100 TA/PLA) and two preparation 
methods (single and double emulsion) which gave spherical microspheres (2.09 ± 1.11 
μm) with smooth surface. Encapsulation efficiency varied depending on the method used 
from 50.3%, to 57.9% and 77.3% for the single emulsion 10/100 and 5/100 TA/PLA, and 
double emulsion method 10/100 TA/PLA, respectively. The in vitro release study showed 
an initial burst of about 10-15% in the first day, followed by a sustained release until day 
20 in all cases. Microspheres were compressed to mini-tablets (diameter 4 mm, thickness 
0.8-1 mm) and episcleral implanted in rabbit eyes ex vivo. The drug diffused into the 
vitreous and aqueous humor rapidly during the first five days, showing a plateau in the 
aqueous humor at day 10. Nonetheless, although these systems showed promising results 
for transcleral drug delivery, authors agreed that further studies are needed to complete 
the evaluation in this setting. Kadam et al. have also evaluated the use of microspheres to 
sustain transcleral choroidal and retinal delivery of triamcinolone acetonide (73). 
Triamcinolone-loaded PLA microparticles (loading 29.5%, size 2.09 µm) were spherical 
and had small pores on the surface, being able to delay in 120 days the complete release 
of triamcinolone in vitro. In vivo delivery was assessed in control and corneal 
neovascularization (CNV) -induced Brown Norway rats after a single injection in the 
posterior subconjunctival space using a 30-gauge needle. Results showed drug levels in 
ocular tissues for 2 months post injection in both groups, and microparticles maintained 
therapeutic concentrations of triamcinolone in choroid-retinal pigment epithelial cells 
  15 
(RPE) and retina during that period of time as well. Entrapped microparticles were still 
observed in the periocular tissues at the end of 2 months post injection.  
Zarei-Ghanavati et al. (74) evaluated the use of triamcinolone-loaded poly (lactic-
co-glycolic) acid (PLGA) 50:50 (Mw 40,000-75,000 g/mol) microspheres (1.9-2.5 µm 
size, 50-85% encapsulation efficiency) in normotensive New Zealand albino rabbits, 
which received an intravitreal injection of 0.1 mL microspheres suspension containing 4 
mg of drug. At pre-set times (3, 7, 14, 28 and 56 days after the injection) triamcinolone 
acetonide levels in eye tissues were analyzed. After 1 week, vitreous drug concentration 
was 0.047 – 0.012 and 0.083 – 0.067mg/mL in eyes that received microspheres and 
triamcinolone suspension, respectively (p= 0.4173). Although, microspheres released 
triamcinolone in a sustained manner, the vitreous concentration declined faster in the 
microparticles group in comparison to the suspension form. Authors suggested a 
migration of smaller microparticles throughout the vitreous cavity as a possible 
explanation of the results.  
Budesonide (Mw 430.5 g/mol) is a potent non-halogenated corticosteroid that has 
the ability to inhibit the expression of several proinflammatory genes, inhibiting 
inflammatory symptoms such as edema and vascular hyperpermeability at nanomolar 
concentrations (75). Kompella et al. have successfully encapsulated budesonide in PLA 
microparticles (3.60 ± 0.01 µg) (76). Authors showed release of budesonide from PLA 
microparticles over a 6-week study period and a cumulative budesonide release at the end 
of the study of 23% of the initial drug loading. Microparticles were subconjuntivally 
injected in rat eyes to determine retina, vitreous, lens and cornea drug levels up to 14 days. 
Authors detected drug levels in all tissues of the injected eye but not in the contralateral 
eye, suggesting that the contribution of systemic absorption and recirculation was 
minimal. About drug levels on day 14, they were higher in the microparticle group 
compared to the solution group in all cases, showing the utility of these systems in 
sustaining drug delivery of budesonide in eye tissues. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
Several studies have demonstrated the utility of the administration of 
Cyclooxigenase-2 (COX-2) selective inhibitors to reduce prostaglandin-induced retinal 
inflammation and blood-retinal barrier breakdown during diabetes (77-79). Celecoxib is 
  16 
a potent COX-2 inhibitor whose oral administration reduces VEGF mRNA and vascular 
leakage in rats (80). However, long-term oral administration of high doses of celecoxib 
may led to systemic toxicity (81). For that reason, the use of alternative routes such as the 
intravitreal and periocular, have been proposed to provide significantly higher local levels 
of celecoxib to the retina. In this regard, Amrite et al. (82) developed biodegradable 
celecoxib-loaded PLGA microparticles (mean particle size 1.11 ± 0.08 μm, ζ potential 
−38 ± 0.56 mV, loading efficiency of 51.48% ± 0.42%). These particles released the drug 
in vitro in a biphasic manner over a period of 60 days, showing a release rate that was 38-
fold lower for the microparticles than with the suspension dosage form. In the diabetic 
animals that received celecoxib-PLGA microparticles, the PGE2 secretion was 12.2 ± 1 
pg/mg in the ipsilateral eye, which was significantly lower than the diabetic or diabetic + 
placebo groups. The levels in the ipsilateral eye in the animals that received the celecoxib 
microparticles were significantly lower than the levels in the contralateral eyes. The 
VEGF levels in the diabetic + celecoxib microparticles in the ipsilateral eye were reduced 
by 40% to 287 ± 92 pg/mg protein. There was a ~50% inhibition of the vascular leakage 
in the ipsilateral eyes of the celecoxib-PLGA microparticle-treated group. Drug levels in 
the ipsilateral eye were 0.66 ± 0.33, 0.79 ± 0.34, 0.23 ± 0.1, and 3.68 ±3.01 ng/mg tissue, 
respectively, in the sclera-choroid, retina, vitreous, and the cornea. The morphometric 
analysis of the retina revealed no significant differences in the thickness of the neural 
retina, Outer Nuclear Layer (ONL), or Inner Nuclear Layer (INL) between the celecoxib-
PLGA microparticle group and the control group indicating no degeneration or atrophy 
of the retinal tissue. Results of this study revealed the safety and effectiveness of a 
periocular microparticulate delivery system of celecoxib in inhibiting diabetes-induced 
blood–retinal barrier leakage. 
Ketorolac (Mw 255.3 g/mol) is a drug that belongs to the group of NSAIDs which 
has nonselective inhibitory activity of the COX enzyme and whose neuroprotective 
activity has been recently studied by Nadal-Nicolás et al. (83). Authors evaluated the 
effect of an intravitreal solution of ketorolac or ketorolac-loaded PLGA microspheres on 
retinal ganglion cells survival after optic nerve crush in rats (at 0.5 mm from the optic 
disc). Microspheres (27 µm size, 114.3 µg drug/mg microspheres, encapsulation 
efficiency 88%) were able to release ketorolac in vitro for 30 days in a controlled fashion, 
showing an initial burst release effect during the first 24 hours, and delivering the drug 
for 30 days following a zero order release kinetic (2.34 µg ketorolac/mg MP/day). 
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Ketorolac-loaded microspheres were still observed in the ventral retina 14 days after 
intravitreal administration. Nonetheless, regarding retinal ganglion cells survival authors 
observed that low ketorolac doses slowly released from microparticles were not enough 
to protect retinal ganglion cells in an acute injury, suggesting that this type of injury 
probably requires higher doses of the active substance.   
Photoswitch drugs 
Photoswitch compounds are light activated and enable bi-directional photocontrol of 
neural membrane potential. The activation of these molecules consists on a transition 
from their trans to cis form in light responsive manner, providing drugs that can be 
delivered to cells to make them light sensitive. Progress has been made on several 
approaches to use these compounds to restore vision to a retina devoid of rods and cones, 
offering a substantial hope for vision restoration in the future (84). In this regard, 
Groynom et al. have recently investigated the loading and delivery of quaternary 
ammonium-azobenzene-quaternary ammonium (QAQ) and diethylamine-azobenzene-
quaternary ammonium (DENAQ), molecules with high light sensitive, in microspheres 
prepared with PLGA and PLA, comparing their loading efficiency and release profiles, 
for a possible utility in ophthalmology (85). The highest amount of drug loaded into 
microspheres was found when systems were prepared with PLGA 502H (51.15±17.77 μg 
of QAQ/mg of microspheres and 62.37±18.59 μg of DENAQ/mg of microspheres). This 
tendency was also observed in the release studies, where PLGA microspheres showed the 
highest cumulative release among all the systems for both QAQ and DENAQ. 
Approximately 87% of QAQ was released on the first 42 days, with no appreciable burst 
effect. For DENAQ, approximately 5% was released on day 1 in a burst release, followed 
by a plateau and relatively linear release from day 7 to day 42 leading to delivery of 95% 
of the drug. Although the loading and delivery of the photoswitch drugs from the 
biodegradable microspheres showed in this study can be optimized, these might be 
promising results for potential therapeutic applications in the ophthalmology area.  
  18 
Table 1 Summary of small molecules microencapsulated for the treatment of chronic diseases of the optic nerve/retina  
 
 
Active molecules IDDS Preparation method Sustained drug 
release 
Optic nerve/Retinal 
disease 
In vitro or in vivo 
experiments 
References 
Corticosteroids Dexamethasone pSiO2 
microparticles 
Thermal oxidation 60 days (in vitro and 
in vivo) 
Retinal vascular 
diseases 
New Zealand Red 
rabbits 
Hou H et al., (68) 
PEAs 
microspheres 
Solvent evaporation 
method 
90 days (in vitro) Sprague-Dawley 
rats  
Andrés-Guerrero V et 
al., (69) 
Triamcinolone 
acetonide 
PLGA 
microspheres 
(RETAAC 
system) 
Solvent evaporation 
method 
- Patients with 
diabetic macular 
edema 
Cardillo el al. (71) 
PLA 
microspheres 
Solvent evaporation 
method 
60 days (in vitro) Cadaver New 
Zealand rabbit 
eyes 
Blatsios et al. (72) 
PLGA (50:50) 
microspheres 
Solvent evaporation 
method 
60 days (in vivo) New Zealand 
albino rabbits 
Zarei-Ghanavati et al. 
(74) 
Budesonide PLA 
microparticles 
Solvent evaporation 
method 
15 days 
(nanoparticles) and 42 
days (microparticles) 
Sprague-Dawley 
rats 
Kompella et al. (76) 
Nonsteroidal anti-
inflammatory drugs 
(NSAIDs) 
Celecoxib PLGA (85:15) 
microparticles 
Solvent evaporation 
method 
60 days (in vitro and 
in vivo) 
Diabetic Retinopathy Sprague-Dawley 
rats 
Amrite et al. (82) 
Ketorolac PLGA (85:15) 
microspheres 
Solvent evaporation 
method 
42 days (in vitro) Sprague-Dawley 
rats 
Nadal-Nicolás et al. 
(83) 
Photoswitch drugs QAQ /DENAQ PLGA (50:50) 
and PLA 
microspheres 
Emulsion technique 100-150 days (in 
vitro) 
Retina devoid - Groynom et al (85) 
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4.- MICROENCAPSULATION OF PEPTIDES AND PROTEINS FOR THE 
TREATMENT OF CHRONIC DISEASES OF THE OPTIC NERVE AND RETINA 
The encapsulation of peptides and proteins has been one of the most fascinating 
defiance over the last years in the pharmaceutical technology area. In spite of their 
promising characteristics as therapeutic agents, they have some serious constraints. The 
main limit is their structural complexity and high molecular weight that have to be 
maintained with regard to keep their biological activity. Diverse methods like double 
emulsion, phase separation, hot-melt extrusion and spray drying, each one with their own 
conveniences and inconveniences are used to microencapsulate proteins. The method of 
preparation must assure the biological activity of the encapsulated biotechnological 
products not only during its elaboration, but also during storage and use of the 
microparticles (86-89). The W/O/W emulsion solvent technique is the most applied 
method for the preparation of these systems. Using this procedure, peptides and proteins 
are initially dissolved in the aqueous inner phase. However, the employment of 
macromolecules solution needs the evaluation of the specific assets through protein 
nature and further use, toward to avoid the associated potential leading dangers that might 
compromise its stability (90, 91). To bypass those risks, proteins and peptides can be 
microencapsulated in its solid state. It has been described that protein at solid state is 
kinetically cornered in the initial form, thus the conformational modification could be 
largely restricted (92, 93). In this regard, several authors are engaged on the protein 
microencapsulation following S/O/O methods in which the solid protein is suspended in 
the internal organic phase which is subsequently emulsified with an also organic external 
phase. Once created under these preparation conditions, protein unfolding is extremely 
slow (90). Although issues may rise regarding residue of oily phases that could lead to 
regulatory and immunity problems (94), the S/O/W method might decrease these 
problems. Whatever S/O/O or S/O/W approaches are used, it is essential to use a protein 
powder with a small particle size at the initial S/O suspension step (95). To obtain the 
desired protein powder this, lyophilisation of a water solution protein with additives is 
largely employed (96, 97). Moreover, the effect of lyophilisation on the biological active 
compound stability has been researched thoroughly, as denaturalization and aggregation 
are usual phenomena along freezing and subsequent dehydration, still in the presence of 
lyo-protectors (90). The alternative employment of spray-drying also has its constraints. 
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At the moment, spray-drying is applied for protein microencapsulation. In this method, 
lyophilisation of protein is needed again ahead dispersion and homogenization in an 
organic polymer solution. Then, the protein/polymer suspension created is sprayed over 
a heated nozzle and organic solvent is immediately removed by a rapidly vaporization by 
a hot gas flow. Even though the period of airing to high temperatures is usually short, it 
could have an adverse impact on protein stability (90). In addition is attainable to direct 
spray the W/O emulsion where protein is soften in the water phase (98). The benefit of 
this technique is that no high temperatures are used to eliminate organic solvent. However, 
the creation of a W/O emulsion does not assure proteins from the unfolding and 
aggregation development commented beneath.  
 
Clinical use of peptides and proteins in neurodegenerative diseases has been under 
investigation in the last years. Macromolecules such as anti-VEGF, neurotrophic factors, 
matrix metalloproteinase, erythropoietin, serpin-derived peptides, connexin mimetic 
peptides among others have been encapsulated in microparticles for intraocular purpose. 
4.1.- Anti-VEGF therapy 
As mentioned before, VEGF is a protein that plays a critical role in angiogenesis 
and vascular hyper-permeability associated with wet AMD (99). VEGF family consists 
of various ligands (VEGF-A, VEGF-B, VEGF-C, VEGF-D and PIGF), VEGF-A being 
the dominant mediator of pro-angiogenic signaling. Several therapies have been 
developed with the objective of inhibiting VEGF for the treatment of ocular pathologies. 
These therapies include VEGF inhibitors such as bevacizumab, ranibizumab and 
aflibercept.  
Currently, the treatment of wet AMD with anti-VEGF therapies is based on one-
month injections of the active compound in solution. Unfortunately, the effect is short for 
a chronic disease, with estimated intravitreal half-life values of several days in all cases. 
That is why the benefit of these new active compounds could be largely optimized by 
including them in drug delivery systems able to release the compounds for longer periods 
of time (ideally several months). Several research groups have explored the possibility to 
include these new active compounds in microspheres for intravitreal administration. 
Some of them have focused on the development of efficient microencapsulation methods 
for these anti-VEGF agents and in some cases the further evaluation of the 
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microencapsulated protein activity in vitro has been also performed. For example, Li et 
al (100) elaborated bevacizumab-loaded microspheres with PEG-PLA (PEG -5000g/mol 
and PLA -5000g/mol-) polymer by O/A emulsion solvent evaporation method using 
different emulsification techniques. The microparticles obtained (2-10 m) showed a 
loading efficiency of 93.6% (with an initial amount of active compound in the preparation 
of 5 mg) and were able to sustained release the protein for 91 days. Unfortunately, no 
bioactivity studies were performed to confirm the integrity of the protein after the 
microencapsulation process. Elsaid (101) prepared “Trojan” microparticles loaded with 
ranibizumab. They first prepared ranibizumab-loaded chitosan (Mw< 400,000g/mol) 
nanoparticles (elaborated by ion gelification using plain chitosan, chitosan combined with 
hyaluronic acid or chitosan chemically modified by the inclusion of N-acetyl-Cys groups) 
The initial amount of protein included in nanoparticles was fixed in 5 mg. Subsequently 
the nanoparticles (17-350 nm) were included in PLGA (85:15; Mw 149,000 g/mol) 
microparticles by addition to the inner phase of a W/O/W emulsion. The best protein 
entrapment results were obtained when N-acetyl-Cys chitosan was used, reaching a 69%. 
Authors suggested that the presence of Cys might improve the protein solubility and also 
the protein entrapment by formation of disulfide bonds. When the in vitro release of the 
different prototypes was performed, the Trojan particles prepared with these 
nanoparticles showed the lowest burst effect and a prolonged release profile. Authors 
showed the absence of citotoxicity of the systems proposed in ARPE-19 and HUVECs 
cells. Furthermore, they also demonstrated that the released protein maintained its 
antiangiogenic nature by evaluation migration in HUVECs cells and by performing 
capillary-like tubules formation studies. Authors concluded that the systems created 
might be considered interesting platforms for the delivery of active anti-VEGF proteins 
after intravitreal administration. 
Moreno et al (102) performed a deep analysis of different technological 
parameters that could influence the stability of ranibizumab and aflibercept after 
microencapsulation. To this, they evaluated different additives to be included in the inner 
phase of a W/O/W emulsion demonstrating the beneficial effect of bovine serum albumin 
(BSA) that partially avoided protein denaturalization during emulsification. Furthermore, 
they also studied the influence of different solvents and solvent combinations in O-phase 
of the emulsion. Among the different organic phases evaluated, triacetin and ethyl acetate 
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resulted the best candidates for aflibercept microencapsulation while in the case of 
ranibizumab only triacetin showed significant better results in terms of protein stability. 
Other authors have moved forward. Not only optimizing the microencapsulation 
processes of anti-VEGF compounds but also demonstrating the real utility of the systems 
proposed in vivo, (in healthy animals or, even better, in some cases in retinal diseases 
animal models). 
In this sense, Yandrapu and co-workers (99), published a very interesting work 
exploring the combination of nano- and microparticles for the sustained release of 
bevacizumab. Several “Trojan prototypes” were proposed. The most successful approach 
involved an initial protein adsorption onto PLA (1.0 dL/g) nanoparticles (2.5 mg 
protein/500 mg PLA; final mean particle size 265 nm) followed by their entrapment in 
PLGA (50:50; 0.67 dL/g) microspheres previous porosification by the supercritical 
infusion and pressure quench technology. The so-prepared particles (10% w/w PLA np 
content in the final formulation; microspheres final particle size 11.6m) led to in vitro 
release of the active compound in a sustained manner for 4 months. ELISA; SEC, CD 
and SDS-PAGE were employed to evaluate the protein stability after release 
demonstrating that the microencapsulation technique proposed do not alter neither the 
conformation nor the activity of bevacizumab. In vivo studies were performed in rats. 5 
L of microparticle suspension (30% w/v) were intravitreally injected in the right eye of 
healthy rats and the same amount of protein (7.2 g) was also administered in solution to 
the left eye of each animal for comparison. In eyes treated with encapsulated protein 
(Alexa Flour 488 conjugated bevacizumab) it was detected by noninvasive ocular 
fluorophotometry for two months while fluorescence disappeared two weeks after 
injection in eyes treated with the plain protein solution. Two months post-dosing eyes 
were enucleated and protein was quantified by inmmunoassay in different ocular tissues 
from the anterior and posterior segment. Bevacizumab was detected mainly in vitreous, 
retina and choroid-RPE only in eyes treated with microspheres. All these results 
confirmed the high potential of the new methodology proposed for microencapsulation 
of active proteins system for neurodegenerative diseases. 
Ye and co-workers (103) used a different technological approach to create 
bevacizumab-loaded PLGA microspheres. In this case a S/O/hO emulsion was performed. 
Authors achieved pharmacokinetic studies to “provide evidences for clinical application” 
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of this kind of drug delivery system. The intravitreal injection of 12.75 mg of 
microspheres (protein loading of 0.098 mg of protein/mg of microspheres and mean 
particle size of 2-7 m) was performed in the left eye of New Zealand albino-rabbits and 
a bevacizumab solution in the same concentration (125 mg/0.05mL) was injected in the 
right eye. For 42 days, at several time points, three animals were sacrificed and the eyes 
were enucleated. The distribution of the active protein was evaluated in ocular tissues by 
immunofluorescence staining and its concentration in aqueous humor and vitreous was 
determined by ELISA. Results showed that the active protein was still present in ocular 
tissues 42 days post-injection, especially in retina, choroid, iris, ciliary body and anterior 
chamber angle. The concentration of bevacizumab in aqueous humor and vitreous after 
administration of microspheres was higher than of bevacizumab in solution. The 
pharmacokinetic parameters calculated revealed area-under-the curve values in the 
vitreous 2-fold higher from bevacizumab-loaded microspheres compared to the plain 
solution. Also important increase in Cmax values in the vitreous were observed (249 
g/mL for microspheres and 156 g/mL for protein solution). Results showed the utility 
of PLGA microcarriers for anti-VEGF proteins long-term delivery in the vitreous in the 
treatment of chronic retinal diseases. 
In an attempt to improve the microencapsulation process Zhang et al (104) used a 
coaxial electrospray method to prepare PLGA microparticles loaded with ranibizumab. 
This method creates small drops with core-shell distribution, formed by an outer layer of 
organic PLGA (50:50 12,000 g/mol) solution and an inner layer of protein saline solution 
and ethylene glycol (final protein concentration in saline solution of 1.2 mg/mL). The 
final particles, obtained after lyophilization, had a very uniform size distribution 2.4 m 
and high encapsulation efficiency of 70%. Furthermore, the microencapsulation process 
occurred maintaining the protein structure according to ELISA assays. Unfortunately, 
authors did not perform in vitro protein release from the systems created, but, on the 
contrary, used a fluorescent small molecule to this (rhodamine-6G). At these conditions 
the microspheres were able to in vitro release the compound for one month. Also 
microparticles loaded with a fluorescent marker (1,1’-Dioctadecyl-3,3,3’,3’-
tetramethylindocarbocyanine perchlorate) were employed to test the safety of the 
formulation in healthy animals (chick model). After intravitreal injection particles (0.002, 
0.02 mg and 0.2 mg) were distributed in various retina layers: the ganglion cells layer, 
the inner plexiform layer and even in the inner nuclear layer. Histological studies were 
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performed one day after injection (short term study) and 12 days after injection (long term 
studies). No reaction (inflammation or retinal cell death) was observed, at any time of the 
study. However, when the number of particles was increased to 0.2 mg, microglia 
activation and retinal cell death was observed in the short term study. Further studies with 
ranibizumab-loaded microspheres would be necessary to complete this interesting 
technological approach. 
4.2.- Neurotrophic factors 
Neurotrophic factors are capable of attenuating or reversing neuronal 
degeneration. They are secreted by tissues throughout the body but are most abundant in 
the central nerve system. The retina contains Central Nervous System (CNS)-associated 
neurons making it an excellent potential site for neurotrophin therapies (105), such as 
BDNF (brain-derived neurotrophic factor), CNTF (ciliary neurotrophic factor) or GDNF 
(Glial cell-line derived neurotrophic factor), being the last one the most studied at the 
moment. 
GDNF is a potent neurotrophic factor known to promote the development and 
survival of neurons. It was originally identified as a potent survival factor for midbrain 
dopaminergic neurons by Lin et al (106). This neurotrophin is the founding member of 
GDNF family ligands (GFLs), a subgroup of peptide trophic factors related to 
transforming growth factor-β (TGF-β) superfamily. Like other neurotrophic factors, 
GDNF belongs structurally to the cysteine knot proteins and thus, GDNF is a disulfide-
linked homodimeric protein with a molecular weight of 30,400 g/mol and a 134 amino 
acid sequence(107).  
GDNF is widely expressed in a large variety of central and peripheral neurons 
with an indispensable role in growth, differentiation, and survival (108, 109). In this 
regard, the use of exogenous growth factors as GDNF have shown to be an interesting 
therapeutic approach for neurodegenerative diseases including Parkinson’s disease, 
Alzheimer’s disease and neurodegenerative ocular diseases (110-113). In addition, recent 
studies have reported that long-term expression of GDNF in photoreceptors provides a 
neuroprotective effects in diseases like retinitis pigmentosa (114), retinal transplants 
(115), glaucoma (116) and diabetic eye disease (117). In the retina, in vitro and in vivo 
studies have shown the potential of GDNF for rescuing retinal photoreceptors and 
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ganglion cells functions during retinal degeneration (118). Moreover, GDNF seems to 
protect RGCs after optic nerve transection (119, 120) and following retinal ischemia 
(121). Several authors have explored the use of GDNF-loaded microspheres for the 
treatment of ocular diseases. 
 
Andrieu-Soler et al. (122) prepared GDNF-loaded PLGA microspheres by 
W/O/W emulsion solvent evaporation method using PLGA 374.5/25. Polyethylene glycol 
was included in the inner aqueous phase to protect GDNF during the emulsification 
process. A mixture of miscible and non-miscible solvents (3:1 methylene 
chloride:acetone) were used in the organic phase. Particles with a mean particle size of 
2710 m were able to encapsulate 1.26 g GDNF/mg microsphere (encapsulation 
efficiency 92%). In vitro release studies performed with radiolabeled GDNF, 
demonstrated that the created systems were able to control the release of the protein. After 
a burst release of the 35% of the dose in the first 24 hours, a slow delivery of the 
neurotrophic factor occurred at 10 ng/day for 56 days (end-point of the release study) 
when 60% of the total dose had been released. For in vivo experiments, rd/rd1 mice were 
used. This animal model is characterized by very fast retina degeneration, with massive 
loss of retinal cells by day 28 post-natal. Particles were suspended in a mixture of 
polysorbate 80, mannitol and carboxymethylcellulose in water (1 L containing 0.3 mg 
of microspheres, GDNF dose of 0.38 g) and intravitreally injected. The extent of retinal 
degeneration was determined after animal euthanasia at post-natal day 28, coincident with 
the complete photoreceptors degeneration in this animal model, 17 days after the 
intravitreal injection. No vitreous reaction or retinal folds were observed, demonstrating 
the safety of PLGA microspheres. However, in two of the 44 eyes injected with 
microspheres (14 with GDNF-loaded microspheres, 18 with non-loaded microspheres 
and 12 with GDNF-loaded microspheres in which the protein had been previously 
denaturalized) microspheres agglomerated close to the retina promoting retinal folds but 
no retinal detachment. While non treated eyes showed only one layer of cells in the ONL 
(56 nuclei/400 m), 3 to 5 rows of cells were observed in eyes treated with GDNF-loaded 
microspheres (123 nuclei/400 m). Interestingly, a slight high amount of nuclei was 
observed in animals treated with blank microspheres (91 nuclei/400 m) compared with 
the non-treated animals. An increment in rods survival was also observed for eyes treated 
with GDNF-loaded microspheres, in comparison to non-treated eyes and with eyes 
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injected with non-loaded microspheres of with microspheres loaded with inactivated 
GDNF. Furthermore, after administration of GDNF-loaded microspheres it was observed 
a reduction of proliferation of retinal Müller in the subretinal space, in comparison to the 
other groups evaluated, demonstrating also a reduction in the inflammatory reaction. 
Finally, electroretinogram recordings were performed at shorter times (12 days after 
injection) to evaluate photoreceptors functionality. Rods from eyes treated with non-
loaded microspheres or with microspheres loaded with denaturalized GDNF do not 
respond to light stimulation leading to b-wave amplitude very small. On the contrary, in 
the case of GDNF-loaded microspheres injected eyes there was a statistically significant 
increment in the b-wave amplitude, suggesting not only anatomical but functional rescue 
of photoreceptors. This strategy could be especially useful in diseases characterized by a 
loss of photoreceptors such as RP. 
Ward et al (123) achieved the protection of retinal ganglion cells in a glaucoma 
animal model (mice) after injection of GDNF-loaded microspheres. The particles were 
prepared according to the W/O/W emulsion solvent evaporation method using PLGA 
(PLGA Resomer® 503H 50:50 Mn = 25,000). Bovine serum albumin was included in the 
inner aqueous phase in combination with the active protein to protect it and a mixture of 
methylene chloride and trifluoroethanol (1:4) was chosen as organic solvent. 
Microspheres (mean particle size of 10 m) released GDNF in a sustained fashion over 
71 days, preceded by an initial burst release in which the 59% of the loaded protein was 
delivered within the first 24 hours. The in vivo study was performed in a spontaneous 
glaucoma animal model (DBA/2J mice). This animal model suffers progressive retinal 
ganglion cells degeneration, with reduction of 30% at 8 months (called “early 
degeneration”) and of 80% at 10 months (“late degeneration”). 1 L of microspheres 
suspension in PBS (0.02 mg of microspheres with a total GDNF dose of 0.707 g) was 
tested in the animal model. Four protocols were performed. In three of them animals were 
exposed to several intravitreal injection of particle suspension each 2 months (3 or 4 
injections). Animals were sacrificed and evaluated at 4, 6 and 8 months for protocol 1, at 
13 months for protocol 2 and at 15 months for protocol 3. In a fourth protocol animals 
were injected only in the “late degeneration” time period (at 8 and 10 months) and were 
subsequently sacrificed at 12 months. Authors intended to cover both “early” and “late” 
RGC degeneration and “early” and “late” microspheres administration. The 
determination of RGC degeneration was performed by quantifying RGC densities. After 
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intravitreal administration of GDNF-loaded microspheres at 2, 4 and 6 months, the “early 
degeneration” was evaluated, showing RGC rescue of 18.6% at 8 months. Furthermore, 
these animals underwent a prolonged neuroprotection without the need of further 
injections, so when they were evaluated at “late degeneration” stage of the disease 
(Protocol 3) the 15-month-old treated animals showed 3.5 times greater RGC survival in 
comparison with non-treated animals. Similarly, when the treatment was set at an early 
stage of the degeneration and it was maintained each two months until 13 months 
(Protocol 2) the RGC density was 2.9 higher in treated eyes. Interestingly, results from 
protocol 2 and 3 showed that the administration of GDNF-loaded microspheres promoted 
the shift in the onset of massive RGC degeneration from 8-10 months to 13-15 months. 
Finally, when GDNF-loaded microspheres were injected in the “late degeneration” step 
of the disease (at 8 and 10 months, protocol 4) also a neuroprotective effect was achieved 
although the RGC density in animals from this group was considerably less than densities 
from all others. In conclusion these authors demonstrated that GDNF released from 
GDNF microspheres significantly promoted RGC survival, being the early treatment 
alone sufficient for this survival effect. Furthermore, the RGC rescue results observed in 
long-term studies supported the potential of the systems created for the treatment of 
chronic neurodegenerative diseases such as glaucoma. One year later, Jiang et al (124) 
evaluated GDNF-loaded microspheres (elaborated with the same protocol) in a rat model 
of glaucoma. This animal model is created by injection of hypertonic (1.9 M) saline 
solution into the episcleral vein, which promotes a chronically elevated IOP for eight 
weeks that simulates glaucoma events in the retina and optic nerve. GDNF loaded 
microspheres were suspended (at 2 and 10%) in PBS and intravitreally injected. Animals 
treated with the higher microspheres concentration showed significant increase in RGC 
and axon survival, a reduction in the loss of retinal IPL (inner plexiform layer) thickness 
and a decrease glial activation in both retina and optic nerve, compared with non-loaded 
microspheres. Furthermore, the treatment with loaded GDNF microspheres moderately 
reduced cupping on the optic nerve head. Later, Kyhn et al (121) evaluated the 
neuroprotective effect of the same GDNF-loaded PLGA microspheres (prepared 
according to Ward et al., 2007) in a pig model of acute retinal ischemia. In this work 
microspheres (2 mg in 0.2 mL of PBS; total GDNF dose of 70.7 µg) were intravitreally 
injected three days after the ischemia insult. The left eye was injected with loaded and 
non-loaded microspheres and the right eye of each animal was left as control. Histological 
studies were performed after animals’ sacrifice at the end of the study (day 42-49 post 
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injection) to evaluate potential retinal damage and to quantify cells in the RGC layer. In 
the animal model used, the pressure-induced retinal ischemia affects the inner retinal 
layer, the RGC layer becomes pathologically thin or almost absent with the nerve fiber 
layer thinned as well. Furthermore, edema appears in the plexiform layers and the inner 
nuclear layer. However, for animals treated with GDNF-loaded microspheres less 
destruction of the inner retinal layers, including the RGC layer was observed, in 
comparison to non-treated retina and with retinas treated with non-loaded microspheres. 
Quantitatively, the neuroprotective effect of the microsystems proposed was 
demonstrated by immunohistochemical detection of nuclei in the RGC layer. Eyes 
injected with GDNF-loaded microspheres showed RGC presence more than double that 
seen with blank microspheres. This increase in RGC cells was corroborated by an 
improvement in the retinal functionality, according to the multifocal electroretinography 
studies performed.  
Checa-Casalengua et al (116) also evaluated the neuroprotective effect of GDNF-
loaded microspheres Using PLGA 50:50 (Resomer® 503 35,000 g/mol). In this case rats 
with chronic elevation of IOP, generated via episcleral vein injection of hypertonic saline 
were used as animal models. A new microencapsulation method for proteins was 
proposed by the research group based on the S/O/W emulsion method. The novelty of the 
technique was based on two facts. On one hand, the protein was not pre-treated before 
encapsulation and always remained in its solid state. On the other hand, an oily additive 
(Vit E) was included in the internal phase, promoting additional protein protection, 
release modulation and pharmacological activity itself (antioxidant) (125). The 
microspheres prepared (mean particle size 19 µm; 25.4 ng GDNF/mg microspheres (MS)) 
released in a controlled manner the protein for 133 days. Initially, a burst effect was 
observed with 16 ng GDNF/mg MS delivered in the first 24 hours. After that, several 
steps of relatively rapid and slow release appeared: at 117.3 pg GDNF/mg MS for the 
following 41 days, at 175.2 pg GDNF/mg MS from day 42 to day 77 and at 13.5 pg 
GDNF/mg MS form day 77 to the end of the assay. The biological integrity of the protein 
after the microencapsulation and release process was demonstrated by bioactivity assays 
using photoreceptor explants and cultured RGCs. For the in vivo studies 5 µL of a 
microspheres suspension in PBS (0.5% of microspheres, GDNF total dose of 0.64 ng) 
was intravitreally injected in animals one week after increase of IOP. Eleven weeks post-
injection animals were sacrificed and RGC cells were quantified by counting anti-NeuN 
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positive cells in the ganglion cells layer. In healthy rats values close to 67 cells/mm were 
observed, while in non-treated glaucomatous animals of animals receiving non-loaded 
microspheres this values drops to approximately 20 cells/mm. In eyes treated with 
GDNF/Vit E loaded microspheres values around 51 cells/mm were obtained, 
demonstrating the ability of the microsystem to rescue RGC. Furthermore, the treatment 
proposed was also found to have positive effect on optic nerve axonal preservation, with 
survival values of 73%, in contrast to values around 30% of survival obtained from non-
loaded microspheres of with the same dose of GDNF administered as bolus in solution. 
No obvious side effects on the retinal integrity were noted. 
 
4.3.- Other therapeutic proteins and peptides 
While most of the works developed until now are focused on the intraocular 
administration of anti-VEGF compounds and neurotrophic factors, other proteins and 
peptides have already emerged as interesting active macromolecules to be 
microencapsulated for the treatment of ocular diseases.  
Yao et al (126) microencapsulated matrix metalloproteinase 2 (MMP-2) and co-
administered the particles in the subretinal space with retinal progenitor cells. MMP-2 is 
a protein (Mw approx 72,000 g/mol) able to degrade cell adhesion molecules such as 
CD44 and neurocan involved in the maintenance of the inhibitory extracellular matrix 
subretinal barrier. The interesting strategy explored in this paper was to use a slow release 
of MMP-2 as coadjuvant to enhance the celular integration and promote retinal 
repopulation. Particles were prepared using PLGA (Resomer® 502, 14,000 g/mol) by 
W/O/W emulsion solvent evaporation method. The microencapsulation conditions were 
optimized to create microspheres able to release the protein in one week, time necessary 
to degrade inhibitory extracellular matrix and to allow transplanted cells migration 
without disruption of host retina. Rho-/- mice were used as retinal degenerative recipient 
animals in this study. 1 µL of microspheres (10-20 µm range of particle size) suspension 
(5 ng/mL of released active MMP2) was mixed with RPCs (2 x 105/ µL) and subretinaly 
injected. CD44 and neurocan quantification was performed by immunohistochemistry 
during the following 5 days in eyes from different animal groups. Coincident with the in 
vitro peak MMP-2 release at day 3, an important reduction of both molecules was 
observed also in vivo at the same time. This fact was related with a significantly higher 
retinal progenitor cells migration into the retina, aproximately 3-folds at day 3 and 2-folds 
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at day 5 after injection in comparison to control groups, demonstrating that the strategy 
proposed can be an interesting tool for retinal repair. 
Erythropoietin (EPO) is another promising candidate in the treatment of ocular 
diseases. It is 165 amino acid peptide with a 30,000 g/mol protein. It owns four 
glycosylation sites and thus controls the half-life in bloodstream. It’s mainly produced in 
kidney and fetal liver (127). EPO has been demonstrated to be useful in RGC, 
photoreceptors and RPE cells protection against acute damage and also to offer 
antiapoptotic activity. Furthermore, it stimulates neurite regrowth in RGCs after 
axotomization (128, 129) This neuroprotective and neurodegenerative behavior makes 
EPO an excellent candidate for microencapsulation and intraocular delivery in the 
treatment of retinal and optic nerve diseases. Rong et al (130) prepared EPO-dextran-
PLGA/PLA microspheres (PLGA(50:50):PLA ratio 4:6) for intravitreal administration. 
During the microencapsulation process they first prepared EPO-dextran particles by 
dissolution of both compounds in PEG and water. The solution was lyophilized and the 
powder obtained was suspended in methylene chloride to eliminate PEG. This washing 
process was repeated five times to obtained the EPO-dextran particles that were then 
microencapsulated in PLA/PLGA matrices by the S/O/W emulsion method. The EPO in 
vitro release from the resulting microspheres (PLA/PLGA microspheres in the 40-100 
µm range) was characterized by an initial burst in which 20% of the initial dose was 
released followed by a sustained release in almost 80 days (final % dose released 90%). 
Unfortunately authors did not measured the dextran-EPO particle size. However,  
regarding the low burst effect found, authors claimed that it should be less than 1/20 of 
diameter of the PLA/PLGA microspheres. The incubation of retina explants with release 
media and posterior observation under a phase-contrast light microscopy showed no 
significant differences with EPO fresh solution in terms of neurites’ density and length, 
demonstrating that the microencapsulation procedure employed in this work preserved 
the protein bioactivity. In vivo studies were performed in rats with damaged retinas due 
to an optic nerve crush. In this model RGC apoptosis massively occurred, reaching a peak 
of 30% apoptotic rate one week after the insult and being still observable for up six weeks. 
The intravitreal injection of 1 mg of microspheres in PBS (total EPO dose of 0.125 µg) 
was performed immediately after the retinas’ insult. Also another animal group was 
treated with EPO solution in PBS every two weeks (EPO dose of 0.0312 µg/injection). 
Non-loaded microspheres suspension in PBS and PBS injections were also performed in 
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control groups. Several analyses were performed to determine the retina status after optic 
nerve crushing for eyes treated and untreated. For the first two weeks after damage retinas 
were compared in terms of apoptotic activity via TUNEL study, showing significantly 
fewer apoptotic RGCs for both groups treated with EPO microspheres and with EPO 
solution, 11% and 12% of RGC apoptosis respectively one week after the insult. 
Furthermore, two weeks after the damage, a reduction of proliferation of retinal Müller 
in the subretinal space for groups treated with EPO (both microencapsulated and 
administered in solution) was observed after determination of glial cells activation in 
retina. On the contrary, non-treated animals showed an increment in this parameter, 
related with inflammatory events, with a peak at two weeks after optic nerve crushing. 
Also, to determine the prolonged neuroprotective effect of the microspheres proposed on 
RGC survival, a retrograde labeling of RGCs was performed 4 and 8 weeks after insult. 
The mean density of survival RGCs in EPO microspheres and EPO solution treated 
groups increased in comparison to control and non-treated groups. Globally, this work 
demonstrated that EPO dextran-PLA/PLGA microspheres showed a prolonged 
neuroprotective effect by promoting RGC survival and partially delaying RGC apoptosis 
in the same extent that multiple EPO solution injections, regardless of the side effects 
caused by repeated injections. Two years later, the same authors published another work 
focused on the evaluation of the tolerance of the EPO-dex PLA/PLGA microspheres after 
intravitreal administration in rabbits (5 mg of microspheres/0.1 mL of PBS) (131). 
Tolerance evaluation was performed 1, 2, 4, 8, and 12 weeks after injection. Microspheres 
remained in the lower part of the vitreous of the injected eyes and gradually degraded and 
disappeared at 11 weeks post-injection. No any RGC apoptosis or glial cell activation 
were observed in treated eyes. Furthermore, the retinal inner structure remained unaltered 
by the presence of microspheres. Neither retinal detachment nor inflammatory reactions 
occurred after injection. Not only structural, but also retina functionality evaluation was 
performed by electroretinogram, showing no changes in the b-wave amplitudes after 
blank PLGA microspheres injection. 
Some authors have explored the possibility of using serpin-derived peptides in the 
treatment of choroidal neovascularization (132). These compounds are able to inhibit 
angiogenesis by both inducing endothelial cell apoptosis as well as decreasing their 
migration by increasing adhesion. One of these peptides, named “SP6001” was 
microencapsulated and evaluated in a laser-induced choroidal neovascularization mouse 
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model (NVAMD) in vivo. Before the microencapsulation process, it was complexed with 
a biodegradable cationic polymer (poly-beta amino ester, PBAE) thanks to the negative 
charge of the peptide due to the presence of glutamate residues, in order to protect the 
peptide form degradation and to extend the delivery. The nanoparticles created (mean 
particle size of 119 nm) were tested alone or microencapsulated in PLGA microspheres 
prepared by the inclusion of the peptide nanoparticles in the inner aqueous phase 
following a W/O/W emulsion solvent evaporation method (PLGA 65:35 Mw 40,000-
75,000). The so prepared microspheres (mean particle size 12 µm; peptide encapsulation 
efficiency around 70%, with an initial amount of 0.25 mg of peptide in the formulation) 
showed a cero-order kinetic release for 140 days (without burst effect) at a rate of 8 ng of 
peptide/mg of particle/day, followed by a slightly slow release phase for additional 60 
days. The animal model used in this work undergoes Brunch’s membrane rupture, which 
induces neovascularization in the damaged zone. Two weeks after the insult animals were 
perfused with a fluorescein-dextran solution to easily detect any leakage in retina due to 
neovascularization. Immediately after insult, the intravitreal injection of loaded 
microspheres, loaded nanoparticles or peptide solution were performed in different 
animal groups maintaining a peptide total dose in all cases of 0.1 µg. At short periods (2-
4 weeks) both loaded nano- and microparticles showed significant suppression of 
choroidal neovascularization according to the measurement of neovascularizated areas. 
Interestingly, for longer periods of time, the suppression of the neovascularization was 
only observed in eyes treated with the microencapsulated peptide. This effect was 
observed up 14 weeks after single injection. Fundus photographs showed slow 
disappearance of the microspheres from vitreous that correlated well with the anti-
angiogenic effect observed. This in vivo microspheres’ degradation was at least twice as 
fast as observed in vitro. Authors explained this phenomenon due to the 
microenvironment in the eye that contains enzymes and clearance mechanism not 
considered in the in vitro release study. 
Chen et al. (133) explored a very interesting alternative to promote RGCs survival 
after retinal injure. They nano- and microencapsulated connexin43 mimetic peptide, a 
macromolecule able to provide RGC protection against the increment in blood-brain 
barrier permeability and the endothelial cell loss that occurs after retinal ischaemia when 
Cx43 hemichannels are open in a uncontrolled manner. Nanoparticles (mean particle size 
113 nm; entrapment efficiency 70%) and microparticles (mean particle size 9 µm; 
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entrapment efficiency 97%) were prepared using the W/O/W emulsion solvent 
evaporation method (PLGA 50:50; Mw 13,600 g/mol). After initial burst effect (46% for 
nanoparticles and 29% for microparticles), sustained release of the peptide was observed 
for both preparations. While nanoparticles were able to release the active compound for 
63 days, microparticles extended this delivery time to 112 days. The bioactivity of the 
encapsulated peptide was in vitro confirmed by evaluating the block of Cx43 hemichannel 
in ARPR-19 cells after 8 hours incubation with loaded nano- and microparticles. 
According to this study, particles were able to protect the peptide from degradation, 
sustain its release and therefore prolong its activity. The systems proposed were evaluated 
in a retinal ischaemia-reperfusion rat model. In this model the Cx43 hemichannel 
becomes significantly upregulated and an increment in astrocytes activation is promoted 
in the ischaemic region. These events provoke a significant loss of RGCs at 28 days 
showing large patches devoid of RGC in many areas with only 70% of RGC survival. 
Furthermore, there is an almost complete loss of blood vessel delineation. The 
administration of peptide-loaded nanoparticles and microparticles was performed 
immediately after insult (2 µL of 580 µM peptide in 0.9% saline solution) and the 
potential beneficial effect was observed 28 and 90 day after. Eyes treated with the peptide 
in solution or nanoencapsulated offered fewer patches of RGC loss at 28 and 90 days. 
Although loaded microparticles also reduced Cx43 levels at 28 and 90 days, this was not 
reflected in any RGC rescue. This behavior was explained to insufficient initial peptide 
release from microparticles immediately after retinal damage. Furthermore, according to 
authors, the larger size of microparticles might hinder their diffusion through the vitreous 
to the retina increasing the risk of enzymatic degradation. However, it was concluded that 
microparticles treatment may still provide long-term RGC protection and thus has 
significant potential in the treatment of chronic retinal and choroidal inflammatory 
conditions. 
Isiegas et al (134) evaluated the useful of microencapsulation of proinsulin as new 
therapy in the protection of photoreceptors and intravitreally tested the system proposed 
in a mouse model of retinitis pigmentosa. Proinsulin (Mw approx 10,000 g/mol) is not 
only a low-activity precursor of pancreatic insulin, but it is also produced in other tissues 
and has shown the ability to delay photoreceptors death in retinitis pigmentosa animal 
models (135, 136). Microspheres were prepared by W/O/W emulsion solvent evaporation 
method using PLGA (50:50 Resomer ® RG503H) as polymer matrix. Particle size ranged 
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from 10 to 32 µm with an active compound loading of 3.2 µg/mg microspheres. The in 
vitro release profile of the formulation selected showed an important initial burst when 
more than 60% of the total amount of encapsulated protein was released, followed by a 
sustained delivery of proinsulin for 45 days with a final accumulated release of 90% of 
the total loaded molecule. According to authors, this initial important release might 
contribute to the neuroprotective effect expected for the systems created. The animal 
model selected for this study, rd10 mice, is characterized by a spontaneous mutation of 
the rod-phosphodiesterase (PDE) gene, leading to a rod degeneration that starts around 
P18 and is also followed by cones loss. The photoreceptor death reaches a peak around 
P25 (137). Animals were intravitreally treated with loaded microspheres (total protein 
dose 22.42 ng) at P14 or P15, before the onset of any photoreceptor degeneration. As 
control, the contralateral eye was injected with non-loaded microspheres. Retinas were 
evaluated at P25 in terms of photoreceptor preservation by determination of outer nuclear 
layer thickness and the number of cell rows. Eyes treated with proinsulin-loaded 
microspheres showed higher ONL thickness and number of rows all over the different 
retina sections evaluated from nasal to temporal zones. The attenuation of cell death for 
treated eyes was also observed in retinal organotypic studies ad P22. Furthermore, authors 
evaluated retina functionality by electroretinography. In this animal model the 
electroretinography (ERG) reveals alterations in the physiology of the inner retina as early 
as P18 (before any obvious morphological change of inner neurons) and yet consistently 
with a reduced band amplification by bipolar cells (137). Results demonstrated that the 
treatment with loaded microspheres significantly increased the b-cone, b-mixed and 
oscillatory potential amplitudes compared with values obtained for eyes injected with 
non-loaded microspheres. According to authors, these results might be explained by a 
reduction in rod cell death, leading to structural improvement in the retina and also a 
neuroprotective effect on synapses between rods and bipolar cells improving their 
functionality. 
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Table 2: Summary of peptides and proteins microencapsulated for the treatment of chronic diseases of the optic nerve/retina  
Active molecules IDDS  Preparation 
method 
Sustained drug release Optic 
nerve/Retinal 
disease  
In vitro or in vivo 
experiments 
References 
Anti-VEGF 
agents 
Bevacizumab PEG-PLA microspheres O/A emulsion 
solvent 
evaporation 
methods 
91 days Age-related 
macular 
degeneration 
 
In vitro technological studies Li et al (91) 
Ranibizumab Trojan particles: 
Ranibizumab-loaded 
chitosan (or chemically 
modified chitosan) 
nanoparticles included in 
PLGA (85:15) 
microparticles 
Nanoparticles: ion 
gelation method. 
Microparticles 
W/O/W emulsion 
solvent 
evaporation 
methods 
The best prototypes offer 
release periods higher 
than 180 days 
Bioactivity and cytotoxicity in 
vitro studies (ARPE-19 and 
HUVECs cell lines) 
Elsaid 
(101) 
  
 
Ranibizumab / 
Aflibercept 
No polymer employed 
(article focused on protein 
stability) 
BSA included in the inner 
phase to protect 
Ranibizumab /aflibercept 
W/O/W emulsion 
solvent 
evaporation 
methods 
Non performed In vitro technological studies Moreno et 
al (93) 
Bevacizumab Trojan particles: 
Bevacizumab adsorption 
onto PLA nanoparticles 
included in PLGA (50:50) 
microspheres 
Supercritical 
infusion and 
pressure quench 
technology 
4 months In vivo pharmacokinetic 
studies (healthy rats) 
Yandrapu 
et al (90) 
Bevacizumab PLGA (50:50) 
microspheres 
S/O/O emulsion 
solvent 
evaporation 
methods 
Non performed In vivo pharmacokinetic 
studies (healthy rabbits) 
Ye et al 
(103) 
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Ranibizumab PLGA microparticles: 
Inner layer - protein and 
ethylene glycol 
Outer layer -PLGA (50:50) 
Coaxial 
electrospray 
method 
Non performed 
(rhodamine-6G loaded 
microparticles were able 
to release the marker for 1 
month) 
In vivo tolerance studies with 
microspheres loaded with 
fluorescent marker (healthy 
chicken). 
No in vivo studies were 
performed with ranibizumab 
loaded microparticles 
Zhang et al 
(104) 
Neurotrophins Glial cell-line 
derived 
neurotrophic 
factor (GDNF) 
PLGA (37.5/25) 
microspheres: 
PEG (400) included in the 
inner phase to protect 
GDNF 
W/O/W emulsion 
solvent 
evaporation 
methods 
56 days Retinitis 
pigmentosa  
 
In vivo efficacy studies in rd/rd 
1 mice 
Andrieu-
Soler et al. 
(122) 
PLGA 
(50:50)microspheres: 
BSA included in the inner 
phase to protect GDNF 
W/O/W emulsion 
solvent 
evaporation 
methods 
71 days Glaucoma In vivo efficacy studies in a 
spontaneous glaucoma animal 
model (DBA/2J mice) 
Ward et al 
(123) 
PLGA (50:50) 
microspheres 
W/O/W emulsion 
solvent 
evaporation 
methods 
71 days Retinal ischemia In vivo efficacy studies in a pig 
model of acute retinal 
ischemia 
Kyhn et al 
(121) 
PLGA (50:50) 
microspheres: 
GDNF in solid state 
GDNF/oil additive (Vit E) 
suspension included in the 
internal phase  
S/O/W emulsion 
solvent 
evaporation 
methods 
133 days Glaucoma In vitro bioactivity assays 
(photoreceptor explants and 
cultured RGCs) 
In vivo efficacy assays in 
glaucoma animal model (rats) 
of chronic IOP elevation  
Checa-
Casalengua 
et al (116) 
Other 
therapeutic 
proteins and 
peptides 
 
Matrix 
metalloproteinase 
2 (MMP-2) 
PLGA (50:50) 
microparticles 
W/O/W emulsion 
solvent 
evaporation 
methods 
One week Retinal 
degeneration 
(Celular 
integration and 
promote retinal 
repopulation) 
In vivo efficacy studies in 
Rho-/- mice 
Yao et al 
(126) 
Erythropoietin EPO-dextran nanoparticles 
in PLGA/PLA 
(PLGA(50:50):PLA ratio 
4:6) microspheres 
S/O/W emulsion 
solvent 
evaporation 
methods 
80 days Non specified In vitro bioactivity assays 
(retinal explants) 
In vivo efficacy assays in 
retinal damage animal model 
(rats) due to optic nerve crush 
 
Rong et al 
(130) 
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Serpin-derived 
peptide 
“SP6001” 
PBAE nanoparticles 
Trojan particles: 
peptide-loaded PBAE 
nanoparticles included in 
PLGA (65:35) 
microspheres 
Nanoparticles: 
complexation with 
PBAE 
Microparticles: 
W/O/W emulsion 
solvent 
evaporation 
methods 
140 days Choroidal 
Neovascularization  
In vivo efficacy assays in a 
laser-induced choroidal 
neovascularization mice 
model 
 
Shmueli 
RB et al 
(132) 
Connexin43 
mimetic peptide 
PLGA (50:50) micro- and 
nanoparticles 
W/O/W emulsion 
solvent 
evaporation 
methods 
63 days (from 
nanoparticles) 
112 days (form 
microparticles) 
Chronic retinal and 
choroidal 
inflammation 
Bioactivity in vitro studies 
(ARPE-19 cell line 
In vivo efficacy studies in a 
retinal ischaemia-reperfusion 
rat model) 
Chen et al 
(133) 
Proinsulin PLGA (50:50) 
microspheres 
 
W/O/W emulsion 
solvent 
evaporation 
methods 
45 days Retinitis 
pigmentosa (RP) 
In vivo efficacy studies in rd10 
mice 
Isiegas et al 
(134) 
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4.4.- Other uses of protein microencapsulation involved in the study of optic nerve and 
retinal diseases. Animal models. 
Due to the difficulty of simulate adverse conditions in chronic diseases, different 
strategies have been assayed. Two pioneer research works from 1998 and 2001 already 
explored the utility of protein-loaded microparticles, not to treat ocular diseases but, on 
the contrary, to progressively induce damage in animal retinas simulating events typically 
occurring in ocular diseases, such as neovascularisation. Kimura et al (138) prepared 
cross-linked gelatine microspheres loaded with b-FGF (basic fibroblast growth factor) by 
polyion complexation. b-FGF is a prominent promoter of endothelial cell migration and 
proliferation that stimulates the angiogenic effect. After subretinal injection, particles 
(mean particle size of 40 microns) induced a foreign body reaction from the first week 
after injection. Two weeks post-implantation several events promoted the formation of 
new subretinal vascular vessels, not only due to the inherent effect of the loaded protein 
but also to the release of soluble compounds of infiltrating macrophages and RPE such 
as VEGF. Interestingly authors observed that the choroidal neovascular membranes 
created resulted immunohistochemicaly similar to those developed in AMD. Cleland et 
al (139) prepared microparticles intended for the development of ocular diseases animal 
models as well. They performed poly-glycolic acid microspheres loaded with VEGF. In 
a first step VEGF particles were prepared by spray-freezing procedure including different 
agents to improve the protein stability (trehalose or polysorbate). Subsequently, the so 
prepared protein was included in PLGA microspheres also prepared by spray-freezing 
and further organic solvent extraction (PLGA 50:50 RG502 and RG502H). Authors 
tested these microparticles with therapeutic purposes for the induction of 
neovascularisation in isquemia regions; however authors also explored the potential of 
VEGF-loaded microspheres to increase angiogenensis after intravitreal and subretinal 
injection. In both cases an increase in retinal vessels dilation and the appearance of 
tortuous new vessels was observed five days post implantation. 
 
5.- CONCLUSIONS AND FUTURE TRENDS 
Neurodegenerative diseases of the posterior segment of the eye are directly related with 
blindness. These pathologies have in common that the target site is the retina (or close to 
retinal areas), systemic and topical treatments are not effective (due to the presence of 
ocular effective barriers) and most of them are chronic, multifactorial and elderly related. 
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Patients suffering these diseases can gain benefits from the use of drug delivery systems, 
to slow down the progression of the neurodegenerative events.  
  
One of the most challenging areas in ophthalmology therapy is to decrease the number of 
invasive interventions. This objective can be achieved by the combination of active 
substances and/or the development of drug delivery systems. Currently, retina specialists 
are taking into consideration the utility of the combination of active substances that target 
different pathophysiological mechanisms in retinal complex pathologies. The 
combination of active substances in these therapies has been demonstrated to have 
benefits in comparison with monotherapy. For example in diabetic macular edema 
(DME), a pathology involving vascular endothelial growth factor (VEGF) and other 
inflammatory mediators (140). Although DME is currently first-line treated with 
intravitreal anti-VEGF therapies, some patients are refractory to multiple anti-VEGF 
treatments. In these cases a combination therapy of Anti-VEGF with corticosteroids 
appears a promising alternative (7). Similar therapeutic strategies have been also 
employed in the management of neovascular age-related macular degeneration. Thanks 
to this combination authors have described an overall reduction in the required 
ranibizumab re-treatments compared with ranibizumab monotherapy (141, 142). The use 
of combined therapy in AMD has been extended to non-steroidal antiinflammatory drugs. 
In fact, bromfenac combined with the anti-VEGF in the treatment of wet AMD has 
resulted more effective than single aflibercept therapy (143). 
 
Long term delivery of different active substances can be achieved with the use of multi-
loaded drug delivery systems avoiding successive injections. Microspheres can contain 
different drugs being released in a controlled fashion. Thanks to this therapeutic strategy, 
an improvement in the chronic treatment of neovascular AMD and DR could be gained. 
Combined neuroprotection from biodegradable microspheres can be extended to 
glaucoma by lowering the degeneration occurring in subjects with high levels of IOP as 
well as in normotensive patients. The controlled release of several combinations such as 
biotechnological products with low molecular weight active substances or even several 
low molecular weight drugs with different mechanism of action will result of great 
interest in the coming future. 
The use of microspheres could result beneficial as a combined therapy to be used in 
inherited neurodegenerative diseases. In this case, the combination of gene therapy with 
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neuroprotective drug delivery would be of great interest.  The advances in gene therapy 
and the on-going clinical trials support the fact that this kind of treatments could become 
available in the next coming future. With the help of the slow delivery of neuroprotective 
substances a more rational therapy is available.  
 
The combination of several technological strategies in the same formulation can be an 
interesting tool to improve the benefit of active compounds as well. For example, 
Osswald and Kang-Mieler recently prepared PLGA microspheres loaded with anti-VEGF 
agents (ranibizumab or aflibercept) and included them in an injectable thermos-
responsive hydrogel. This combination allowed the extension of the bioactive compounds 
in vitro release over almost 200 days at constant rate after initial burst release (144). 
 
Microspheres are also emerging tools in the development of chronic animal models of 
degeneration that allow a more physiological approach to the events occurring in the 
clinical scenario.  
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FIGURE LEGENDS 
 
Figure 1: Eye and retina elementary structure. 
 
Figure 2: A) Example of typical release profiles of a hydrophobic small molecule (I) 
hydrophilic small molecule (II) and protein (III) release from PLGA microspheres. B) 
Schematic representation of PLGA microspheres degradation in release media. 
 
Figure 3: Schematic representation of retinal alterations involved in age-related macular 
degeneration and example of patients’ vision. 
 
Figure 4: Schematic representation of retinal alterations involved in diabetic retinopathy 
and example of patients’ vision. 
 
Figure 5: Schematic representation of retinal alterations involved in retinitis pigmentosa 
and example of patients’ vision. 
 
Figure 6: Schematic representation of retinal alterations involved in glaucoma and 
example of patients’ vision. 
 
